Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10755226 | 0.85 | TSHR (0.50) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL15776847 | 0.81 | TDP1 (0.47) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL11678862 | 0.81 | HSD17B10 (0.41) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL30937734 | 0.78 | HSD17B10 (0.41) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL14159967 | 0.78 | TDP1 (0.44) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL6973758 | 0.78 | CYP1A2 (0.47) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL3192674 | 0.77 | TSHR (0.65) | TSHRSMN1; SMN2TDP1HSD17B10CYP3A4 | |
| SCHEMBL700297 | 0.77 | TSHR (0.60) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL16975425 | 0.76 | MAPT (0.50) | TSHRSMN1; SMN2TDP1ALDH1A1KMT2A | |
| SCHEMBL16975422 | 0.76 | MAPT (0.50) | TSHRSMN1; SMN2TDP1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4314005-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| CN-117043172-A | Glucocorticoid receptor agonists | 伊莱利利公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-10-13 | — | — | US | disclosed |
| WO-2022204108-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-106132406-B | β -substituted gamma-amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2020-03-27 | — | — | CN | disclosed |
| US-9937139-B2 | β-substituted γ-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20150218085-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218085-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
| WO-2015117146-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015117146-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| CN-1145623-C | Imidazole derivatives | - | 2004-04-14 | — | — | CN | disclosed |
| EP-0797575-B1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | disclosed |
| US-5959113-A | REACTING A DIKETONE DERIVATIVE WITH AN ALDEHYDE DERIVATIVE; ADMINISTERING TO TREAT ATHEROSCLEROSIS, PSORIASIS, ALOPECIA AND TUMORS | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1175252-A | Imidazole derivatives as protein kinase inhibitors in particular egf-rthyrosine kinase | HOFFMANN LA ROCHE (CH) | 1998-03-04 | — | — | CN | disclosed |
| EP-0797575-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018626-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-11787834-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20150218085-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC3A2, SLC7A1, SLC43A1 | TSHR 3050/4885SMN1; SMN2 2078/4885TDP1 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.